Literature DB >> 22231992

Guest editorial: introduction of Progress in Hematology in this issue.

Yasushi Miyazaki.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22231992     DOI： 10.1007/s12185-011-0998-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  17 in total

1.  Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome.

Authors:  Adel Badran; Akira Yoshida; Yuji Wano; Masato Mutoh; Shin Imamura; Taro Yamashita; Hiroshi Tsutani; Manabu Inuzuka; Takanori Ueda
Journal:  Int J Oncol       Date:  2003-01       Impact factor: 5.650

2.  C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.

Authors:  Y Satoh; I Matsumura; H Tanaka; H Harada; Y Harada; K Matsui; M Shibata; M Mizuki; Y Kanakura
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

Review 3.  Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Pierre Fenaux
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 5.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

6.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

7.  Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors.

Authors:  Masako Iwanaga; Wan-Ling Hsu; Midori Soda; Yumi Takasaki; Masayuki Tawara; Tatsuro Joh; Tatsuhiko Amenomori; Masaomi Yamamura; Yoshiharu Yoshida; Takashi Koba; Yasushi Miyazaki; Tatsuki Matsuo; Dale L Preston; Akihiko Suyama; Kazunori Kodama; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

8.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

9.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

10.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330
View more
  1 in total

1.  Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Authors:  Hiroaki Tanaka; Naomi Shimizu; Emi Tougasaki; Chika Kawajiri; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2013-03-22       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.